Discover and read the best of Twitter Threads about #cfdna
Most recents (6)
Excited to share our TRACERx nature publication on circulating tumor DNA (#ctDNA, #MRD) detection in resectable lung cancer led by @AbboshChris, @AFrankell, @juditkisistok, Thomas Harrison, Aaron Garnett, @nbirkbak and @NickyMcGranahan 👇👇👇 Tweetorial🧵
nature.com/articles/s4158…
nature.com/articles/s4158…
🔬Circulating tumor DNA is a powerful biomarker that can guide and monitor treatment response in early-stage lung cancer patients. Technologies enabling ctDNA detection and characterization are advancing rapidly but we need to understand how to use them in the clinic…
👥 Through collaboration with scientists at @TheCrick and @uclcancer, @AstraZeneca and @Invitae, we developed and validated an anchored-multiplex PCR approach ctDNA detection in 197 patients who donated over 1000 plasma samples to TRACERx.
Very excited to share our new study on determinants of resistance to anti-CD19 CAR T-cells (CART19) in large B-cell lymphomas (LBCLs)! Out today in @Cancer_Cell /1
cell.com/cancer-cell/fu…
cell.com/cancer-cell/fu…
A fantastic collaboration from @StanfordMed and @StanfordCancer led by Brian Sworder, David Kurtz, @StefanAlig, and Matthew Frank with David Miklos & @max_diehn to help improve outcomes following CAR T-cell therapy in lymphomas & beyond /2
We serially profiled plasma & tumor samples from 138 r/rLBCL patients across 2 independent cohorts treated w/ SOC axicabtagene ciloleucel (#axicel #yescarta) @StanfordBMT_CT /3 
Delighted to share our new study nature.com/articles/s4158… introducing PhasED-Seq out today @NatureBiotech.
A fantastic collaboration from @StanfordMedicine led by Dave_Kurtz & Joanne Soo with @max_diehn to help transform #cancer interception & monitoring by improving #LiquidBiopsy #ctDNA detection of #MRD.
Epigenomic biomarkers are becoming more established for #LiquidBiopsy and #CancerScreening, and we have seen the big players positioning themselves in this #epigenomics race recently.
Catching signs of #cancer early is crucially important to the disease management and survival rates, so the question is: how can we find out if there is something wrong going on early enough, ideally in a low-cost assay that can be performed regularly on healthy individuals?
@sbarnettARK Epigenomic biomarkers are becoming more established for #LiquidBiopsy and #CancerScreening, and we have seen the big players positioning themselves in this #epigenomics race recently.
@sbarnettARK Catching signs of #cancer early is crucially important to the disease management and survival rates, so the question is: how can we find out if there is something wrong going on early enough?
@sbarnettARK The first generation of high-throughput technologies was predicated on finding mutated (tumor) DNA in the individual's body (somatic), different from their (normal) DNA. Tumor/Normal (T/N) comparisons of the individual's samples, biopsies or ctDNA will indicate if there
Excited to share our work @NatureMedicine offering a novel framework [MRDetect] for ultra-sensitive cancer monitoring through whole genome mutational integration of cfDNA go.nature.com/2XmxJZv
1/
#LiquidBiopsy #WGS #cfDNA #MachineLearning
👇👇👇
1/
#LiquidBiopsy #WGS #cfDNA #MachineLearning
👇👇👇
Therapy monitoring is a central pillar of modern medicine. And yet, in many areas of oncology, we lack sensitive monitoring tools for residual disease detection. ctDNA carries the potential to change this, but is scarce in low-burden disease.
The central paradigm in the field aims to overcome ctDNA scarcity through deep targeted sequencing of informative sites. However, we show that limited number of fragments imposes a hard ceiling on cfDNA deep targeted sequencing, with sensitivity limited ~1:1,000 per site.
